International Journal of

Blood Research and DisordersISSN: 2469-5696

Archive

 Open Access DOI:10.23937/2469-5696/1410069

Assessment of the Usefulness of Red Cell Indices as a Screening Tool in Haemoglobin E Trait: A Cross Sectional Study

DMHMK Dassanayake, VCP Gunawardena and SB Athauda

Article Type: Original Article | First Published: September 29, 2021

HamoglobinE (HbE) is the second commonest structural haemoglobin variant and results from mutation in the β globin gene causing substitution of glutamic acid for lysine at position 26 of the β globin chain. When coinherited with β Thalassemia it becomes a major health burden. To assess the effectiveness of red cell parameters as a screening tool to identify haemoglobin E traits and to develop a score using red cell parameters which help to identify Haemoglobin E traits in population screening...

 Open Access DOI:10.23937/2469-5696/1410068

Diagnostic Value of miR-26b in Schizophrenia

Ling-ming Kong, Xiao-li Zhu and Li-yi Zhang

Article Type: Original Article | First Published: September 22, 2021

This study aimed to investigate the diagnostic value of peripheral microRNA (miRNA) expression in schizophrenia (SZ). By using an Affymetrix array to identify differentially expressed miRNAs in SZ patients; quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) was used to verify identified microRNA and test major depressive disorder (MDD), generalized anxiety disorder (GAD) and mental retardation (MD) related microRNAs for comparison. The expression levels of miR-1972...

 Open Access DOI:10.23937/2469-5696/1410067

SMYD2 in Leukemia: An Update

Teresa Rubio-Tomás

Article Type: Mini-Review Article | First Published: August 30, 2021

SMYD2 is one of the five members (SMYD1-5) of the Su(Var)3-9, Enhancer-of-zeste and Trithorax (SET) and Myeloid, Nervy, and DEAF-1 (MYND) domain-containing (SMYD) protein family and is it known to methylate histone and non-histone substrates. By methylating a wide range of targets, SMYD2 acts as an oncogene in most cancer types. In this review I will comment on the last publications related to the role of SMYD2 in leukemia and I will refer to more extensive reviews if the reader aims to have a b...

 Open Access DOI:10.23937/2469-5696/1410066

Hypogonadotropic Hypogonadism in a Female Patient with Thalassemia Major

Richmond R Gomes

Article Type: Review Article | First Published: August 28, 2021

Thalassemia refers to a group of inherited diseases characterized by decreased or absent synthesis of normal globin chains. The direct consequence is an imbalance of the alpha and beta globin chain synthesis that results in anemia from ineffective erythropoiesis and hemolysis. The term thalassemia major refers to the severe form that is often associated with life-long transfusion dependent anemia. Hypogonadism is the most frequently reported endocrine complication, affecting 70-80% of thalassemi...

Volume 8
Issue 2